Brought to you by 
Pfizer hands over EGFR inhibitor to partner OSI
06 Jul 2000
Executive Summary
Pfizer is relinquishing to OSI Pharmaceuticals, royalty-free, all development and marketing rights to CP-358,774 (OSI-774), an oral inhibitor of the epidermal growth factor receptor oncogene that the companies have been developing since 1986. Because Pfizer is acquiring Warner-Lambert, which is also developing an EGFR inhibitor, the FTC is requiring it to divest the product.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer hands over EGFR inhibitor to partner OSI
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice